NUVL.NASDAQNuvalent, INC

Form 4: Nuvalent's Chief Legal Officer Executes Stock Options and Sells Shares Under 10b5-1 Plan

Sentiment:

SEC Form 4 Filing


Deborah Ann Miller, Chief Legal Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

  • On August 23, 2024, Deborah Ann Miller, the Chief Legal Officer of Nuvalent, Inc., engaged in transactions involving the company's Class A Common Stock.
  • Miller exercised stock options to acquire 5,000 shares at $18.93 and 6,000 shares at $27.85.
  • Concurrently, Miller sold 11,000 shares at a weighted average price of $85.04, with individual sales ranging from $85.00 to $85.18.
  • These transactions were executed under a pre-existing Rule 10b5-1 trading plan adopted on December 27, 2023.
  • Following these transactions, Miller directly owns 33,300 shares of Class A Common Stock and holds options to purchase 169,154 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine transactions under a pre-arranged trading plan. There's no indication of positive or negative implications for the company's performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The use of a 10b5-1 trading plan suggests a proactive approach to avoid accusations of insider trading.

Comparison to Industry Standards

  • Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
  • Rule 10b5-1 trading plans are a common tool used by executives to sell shares over time, mitigating concerns about trading on non-public information.
  • Comparable companies like Relay Therapeutics or Black Diamond Therapeutics also have executives who utilize 10b5-1 plans and file Form 4s regularly.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders due to the sale of shares by a company officer.
  • The use of a 10b5-1 plan ensures transparency and reduces the risk of negative perceptions regarding insider trading.

Key Dates

DateDescription
January 4, 202325% of the shares underlying one stock option vested.
January 6, 2023Shares underlying another stock option began vesting over four years.
December 27, 2023The reporting person adopted a Rule 10b5-1 trading plan.
August 23, 2024Date of the reported transactions: exercising stock options and selling shares.
August 27, 2024Date of the signature on the Form 4 filing.
January 4, 2032Expiration date of one stock option.
January 6, 2033Expiration date of another stock option.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.